Glucagon-like Peptide-1 Receptor Agonists: Additional Improvement of Erectile Dysfunction in Type 2 Diabetes

References

1. Salonia A. Bettocchi C. Boeri L. European association of urology guidelines on sexual and reproductive health-2021 update: Male sexual dysfunction. Eur. Urol. 2021 80 3 333 357 10.1016/j.eururo.2021.06.007 34183196
   [Google Scholar]
2. Anderson D. Laforge J. Ross M.M. Male sexual dysfunction. Health Psychol. Res. 2022 10 3 37533 10.52965/001c.37533 35999971
   [Google Scholar]
3. Kouidrat Y. Pizzol D. Cosco T. High prevalence of erectile dysfunction in diabetes: A systematic review and meta‐analysis of 145 studies. Diabet. Med. 2017 34 9 1185 1192 10.1111/dme.13403 28722225
   [Google Scholar]
4. Kamenov Z.A. A comprehensive review of erectile dysfunction in men with diabetes. Exp. Clin. Endocrinol. Diabetes 2015 123 3 141 158 25502583
   [Google Scholar]
5. Wang C.M. Wu B.R. Xiang P. Xiao J. Hu X.C. Management of male erectile dysfunction: From the past to the future. Front. Endocrinol. 2023 14 1148834 10.3389/fendo.2023.1148834 36923224
   [Google Scholar]
6. Patoulias D. Popovic D.S. Stoian A.P. Janez A. Sahebkar A. Rizzo M. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials. J. Diabetes Complications 2023 37 8 108529 10.1016/j.jdiacomp.2023.108529 37301063
   [Google Scholar]
7. Yuan P. Ma D. Gao X. Liraglutide ameliorates erectile dysfunction via regulating oxidative stress, the RhoA/ROCK pathway and autophagy in diabetes mellitus. Front. Pharmacol. 2020 11 1257 10.3389/fphar.2020.01257 32903510
   [Google Scholar]
8. Dalaklioglu S. Tasatargil A. Kuscu N. Protective effect of exendin-4 treatment on erectile dysfunction induced by chronic methylglyoxal administration in rats. Peptides 2018 106 1 8 10.1016/j.peptides.2018.05.005 29792899
   [Google Scholar]
9. Lisco G. Bartolomeo N. De Tullio A. Long‐acting glucagon‐like peptide 1 receptor agonists boost erectile function in men with type 2 diabetes mellitus complaining of erectile dysfunction: A retrospective cohort study. Andrology 2024 12 3 633 642 10.1111/andr.13519 37615353
   [Google Scholar]
10. Defeudis G. Di Tommaso A.M. Di Rosa C. The role of antihyperglycemic drugs and diet on erectile function: Results from a perspective study on a population with prediabetes and diabetes. J. Clin. Med. 2022 11 12 3382 10.3390/jcm11123382 35743453
    [Google Scholar]
11. Giagulli V.A. Carbone M.D. Ramunni M.I. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology 2015 3 6 1094 1103 10.1111/andr.12099 26447645
    [Google Scholar]
12. Bajaj H.S. Gerstein H.C. Rao-Melacini P. Erectile function in men with type 2 diabetes treated with dulaglutide: An exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes Endocrinol. 2021 9 8 484 490 10.1016/S2213‑8587(21)00115‑7 34153269
    [Google Scholar]
13. Yang B. Cheng H. Hu Y. Effects of anti-diabetic drugs on erectile dysfunction: A systematic review and meta-analysis. Diabetes Metab. Syndr. Obes. 2025 18 467 478 10.2147/DMSO.S503216 39990178
    [Google Scholar]
14. Salvio G Ciarloni A Ambo N Effects of glucagon‐like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta‐analysis. Andrology 2025 andr.70022 10.1111/andr.70022 40105090
    [Google Scholar]
15. An H. Xie K. Gan H. Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: A drug target Mendelian randomization study. Front. Endocrinol. 2024 15 1448394 10.3389/fendo.2024.1448394 39605940
    [Google Scholar]
16. Pourabhari Langroudi A. Chen A.L. Basran S. Male sexual dysfunction associated with GLP-1 receptor agonists: A cross-sectional analysis of FAERS data. Int. J. Impot. Res. 2025 Epub ahead of print 10.1038/s41443‑025‑01061‑2 40240532
    [Google Scholar]
17. Able C. Liao B. Saffati G. Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: A TriNetX database study. Int. J. Impot. Res. 2025 37 4 315 319 10.1038/s41443‑024‑00895‑6 38778151
    [Google Scholar]